CAW
NKTR icon

Cornerstone Advisors (Washington)’s Nektar Therapeutics NKTR Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2
Closed -$1K – 729
2020
Q2 		$1K Sell
2
-26
-93% -$8.11K ﹤0.01% 658
2020
Q1 		$7K Buy
28
+17
+155% +$5.26K ﹤0.01% 457
2019
Q4 		$3K Buy
+11
New +$3.19K ﹤0.01% 547
2018
Q4 		– Sell
-1
Closed -$1K – 1242
2018
Q3 		$1K Buy
+1
New +$854 ﹤0.01% 1073

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Cornerstone Advisors (Washington)'s NKTR Position: Q3 2020 in Review

Cornerstone Advisors (Washington) sold out of Nektar Therapeutics (NKTR) in Q3 2020, closing a stake of 2 shares — an estimated $1K sold.

Cornerstone Advisors (Washington) first reported a position in NKTR in Q3 2018 and held it in 4 quarters. The position peaked at $7K in Q1 2020. 249 funds tracked by Wall St. Rank hold NKTR as of Q3 2020.

  • Cornerstone Advisors (Washington) reported no remaining Nektar Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Cornerstone Advisors (Washington) sold 2 Nektar Therapeutics shares in Q3 2020, an estimated $1K.
  • Cornerstone Advisors (Washington) first reported a position in Nektar Therapeutics in Q3 2018 and held it in 4 quarters.
  • Cornerstone Advisors (Washington)'s Nektar Therapeutics position peaked at $7K in Q1 2020.
  • 249 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2020.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q3 2020, filed 20 Oct 2020.